Nucleic acids research

Therapeutic DNA vectors carrying edited transfer RNAs to fix genetic code errors

Updated

Abstract

DNA ACE-tRNA vectors as small as 200 base pairs effectively suppress several nonsense mutations in CFTR and REP1.

  • Nonsense mutations account for approximately 11% of all genetic lesions causing disease.
  • Delivery methods for ACE-tRNAs include adeno-associated viral vectors and RNA-lipid nanoparticles, but these have notable drawbacks.
  • DNA delivery methods are highlighted for their cost-effectiveness, durability, and safety compared to viral or RNA-based approaches.
  • Linear DNA ACE-tRNA minivectors show significantly improved bioavailability and reduced immune response in cell and ex vivo models.
  • These minivectors maintain superior biostability compared to traditional plasmid DNA vectors.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

J.D.L. is a co-inventor of a technology presented in this study and receives royalty payments related to the licensing of the technology from the University of Iowa. PCT/US2018/059065, Methods of rescuing stop codons via genetic reassignment with ACE-tRNA; inventors—University of Iowa, inventors J.D.L. and Christopher A. Ahern—pertains to tRNA sequences used in this study. J.D.L. and J.J.P. are co-inventors of technologies presented in this study that pertains to the optimized ACE-tRNA sequences and minivectors. D.A.D. serves as a member of the Scientific Advisory Board of Seawolf Therapeutics and has equity interest in the company.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free